What is KaloCyte?
KaloCyte operates as a preclinical-stage biotechnology enterprise dedicated to solving critical supply chain challenges in transfusion medicine. The company is the developer of ErythroMer, a bio-inspired, freeze-dried synthetic red blood cell designed to serve as a viable alternative to donor-derived blood products. By focusing on shelf-stable, portable blood substitutes, KaloCyte addresses the urgent needs of trauma care environments where traditional blood storage is either logistically impossible or insufficient. The firm leverages a multidisciplinary approach, integrating advanced physiology, bioengineering, and clinical trauma research to bridge the gap between laboratory innovation and life-saving medical application.
How much funding has KaloCyte raised?
KaloCyte has raised a total of $300K across 1 funding round:
Angel/Seed
$300K
Angel/Seed (2020): $300K, investors not publicly disclosed
Key Investors in KaloCyte
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for KaloCyte?
With the recent capital deployment, KaloCyte is strategically positioned to advance its regulatory and clinical roadmap. The primary objective remains the initiation of human clinical trials within the next two to three years. This phase is critical for validating the safety and efficacy of ErythroMer, moving the product from the benchtop to the bedside. Future growth will likely center on scaling manufacturing processes to meet the rigorous standards of global health organizations and military medical units. As the company matures, it will continue to refine its intellectual property portfolio and seek strategic partnerships to facilitate the eventual commercialization of its synthetic blood platform, ultimately aiming to redefine the standard of care in emergency resuscitation.
See full KaloCyte company page
